Literature DB >> 17922596

Omentectomy for gynecologic cancer: how much sampling is adequate for microscopic examination?

Alp Usubütün1, Havva Solak Ozseker, Cigdem Himmetoglu, Serdar Balci, Ali Ayhan.   

Abstract

CONTEXT: Detecting omental metastasis is crucial for staging and treatment of endometrial and ovarian carcinoma.
OBJECTIVE: To determine the optimal omental sampling for omentectomies to ascertain the stage of the disease in a cost-effective way.
DESIGN: We reevaluated 258 omentectomies that were performed due to ovarian or endometrial carcinoma. A total of 116 cases were retrospectively studied, and 142 cases were prospectively studied. For prospective study, 10 to 16 blocks were sampled if the omentum showed no signs of gross tumor. Mean omental block sample frequency of 2 groups with the negative macroscopy but with or without microscopic tumor have been compared using an independent samples t test.
RESULTS: Seven patients had no evidence of tumor metastasis on gross examination but had microscopic tumor metastasis. The mean numbers of blocks were 6.4 for patients having microscopic tumor without macroscopic involvement and 7.8 for patients having neither microscopic nor macroscopic involvement. Approximately twice as many samples were taken in the prospective analysis when compared with retrospective analysis. Two cases with microscopic omental metastasis that had no macroscopic involvement at first impression were reevaluated retrospectively and found to contain 0.3- to 0.5-cm white nodules. The rate of omental metastasis increased with the grade of the tumor (P = .005).
CONCLUSION: Careful macroscopic examination is the most important step in detecting small omental metastasis. For cases with gross tumor, one section is sufficient. If a macroscopic lesion is not detectable and the patient has a high-grade tumor that will necessitate an adjuvant therapy, 3 to 5 samples seem sufficient for staging. Further studies are needed to determine the optimum sample size for tumors having a low risk of metastasis.

Entities:  

Mesh:

Year:  2007        PMID: 17922596     DOI: 10.5858/2007-131-1578-OFGCHM

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  6 in total

1.  Omental adipose tissue-derived stromal cells promote vascularization and growth of endometrial tumors.

Authors:  Ann H Klopp; Yan Zhang; Travis Solley; Felipe Amaya-Manzanares; Frank Marini; Michael Andreeff; Bisrat Debeb; Wendy Woodward; Rosemarie Schmandt; Russell Broaddus; Karen Lu; Mikhail G Kolonin
Journal:  Clin Cancer Res       Date:  2011-12-13       Impact factor: 12.531

2.  What is the importance of omental metastasis in patients with endometrial cancer?

Authors:  Taner Turan; Işın Ureyen; Alper Karalök; Tolga Taşçı; Hilal Ilgın; Levent Keskin; M Faruk Kose; Gökhan Tulunay
Journal:  J Turk Ger Gynecol Assoc       Date:  2014-08-08

Review 3.  Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR).

Authors:  W Glenn McCluggage; Meagan J Judge; Blaise A Clarke; Ben Davidson; C Blake Gilks; Harry Hollema; Jonathan A Ledermann; Xavier Matias-Guiu; Yoshiki Mikami; Colin J R Stewart; Russell Vang; Lynn Hirschowitz
Journal:  Mod Pathol       Date:  2015-06-19       Impact factor: 7.842

Review 4.  Essentials for Pathological Evaluation of Peritoneal Surface Malignancies and Synoptic Reporting of Cytoreductive Surgery Specimens-A review and evidence-based guide.

Authors:  Aditi Bhatt; Suniti Mishra; Loma Parikh; Sandeep Sheth; Imran Gorur
Journal:  Indian J Surg Oncol       Date:  2019-03-19

5.  Sentinel or Selective Omentectomy in Epithelial Ovarian Cancer: New Perspective.

Authors:  Ahmed Samy El-Agwany
Journal:  Indian J Surg Oncol       Date:  2021-01-03

6.  Humanized mouse model of ovarian cancer recapitulates patient solid tumor progression, ascites formation, and metastasis.

Authors:  Richard B Bankert; Sathy V Balu-Iyer; Kunle Odunsi; Leonard D Shultz; Raymond J Kelleher; Jennifer L Barnas; Michelle Simpson-Abelson; Robert Parsons; Sandra J Yokota
Journal:  PLoS One       Date:  2011-09-15       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.